Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

35.3%

6 terminated/withdrawn out of 17 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

150%

12 of 8 completed trials have results

Key Signals

12 with results6 terminated

Enrollment Performance

Analytics

Phase 2
13(81.3%)
Phase 1
2(12.5%)
Phase 3
1(6.3%)
16Total
Phase 2(13)
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT05975021Phase 1Active Not Recruiting

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

Role: lead

NCT04706962Phase 1Active Not Recruiting

TH1902 in Patients With Advanced Solid Tumors

Role: collaborator

NCT04325035Phase 2Completed

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

Role: lead

NCT04389671Phase 2Completed

The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)

Role: lead

NCT04264156Phase 2Terminated

A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age

Role: lead

NCT02617446Phase 2Completed

The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure

Role: lead

NCT03217825Phase 2Completed

Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan

Role: lead

NCT02636868Phase 2Completed

The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age

Role: lead

NCT02528318Phase 2Terminated

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

Role: lead

NCT00215553Phase 2Terminated

KL₄Surfactant Treatment in Patients With ARDS

Role: lead

NCT02074059Phase 2Completed

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

Role: lead

NCT00934362Phase 2Completed

Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease

Role: collaborator

NCT00215540Phase 2Terminated

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Role: lead

NCT00807235Phase 2Terminated

Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants

Role: lead

NCT00578734Phase 2Completed

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

Role: lead

NCT00004500Phase 3Terminated

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

Role: lead

NCT00295230Suspended

Effects of Volume Guarantee With Pressure Supported vs. Synchronized Intermittent Mandatory Ventilation in VLBW Infants

Role: collaborator

All 17 trials loaded